|
市場調查報告書
多發性硬化症市場預測
Multiple Sclerosis Market Forecast
|
多發性硬化症市場預測 是由出版商Datamonitor在2010年07月所出版的。
這份英文市場調查報告書價格從美金15200起跳。
本報告針對多發性硬化症治療藥物目前與未來市場規模定量化，提出商業機會與風險分析、主要上市/實驗藥物評價、2010到2019年世界7大醫療藥品市場各國多發性硬化症治療薬物成長與影響到的主要活動調査結果。
概要
預測方法
免責事項
Abstract
Introduction
With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono' s oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).
Reasons to Purchase
- Quantify the current and future size of the multiple sclerosis drug class market and understand the main commercial opportunities and threats
- Assess key marketed and pipeline drugs, including new oral agents, Acorda' s Ampyra (dalfampridine) and GW Pharmaceuticals' Sativex (nabiximols).
- Understand the country-specific impact of key events in the multiple sclerosis market during the forecast period 2010 to 2019.
Table of Contents
OVERVIEW
- This product contains forecasts for multiple sclerosis drugs across the seven major markets from 2010 to 2019. It has been designed for delivery in an excel data pack format.]
- The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
- Introduction
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
- Disclaimer
|
